Christopher Coccia, DO
Family Medicine · Cullman, ALNPI 1083695696
Payments from drug & device makers
Across 481 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$825
- GSK$796
- Novo Nordisk$770
- Astellas Pharma US Inc$751
- Lilly USA, LLC$332
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,07699%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 109 | $1,666 |
| AstraZeneca | 41 | $825 |
| GSK | 50 | $796 |
| Novo Nordisk | 40 | $770 |
| Astellas Pharma US Inc | 42 | $751 |
| Lilly USA, LLC | 19 | $332 |
| Amgen(2 entities) | 19 | $320 |
| AbbVie(2 entities) | 18 | $319 |
| Johnson & Johnson(2 entities) | 19 | $280 |
| E.r. Squibb & Sons, L.L.C. | 17 | $272 |
| Novartis | 12 | $200 |
| Exact Sciences | 10 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $163 |
| Bayer | 8 | $163 |
| Dexcom, Inc. | 8 | $144 |
| Merck | 9 | $139 |
| Boehringer Ingelheim | 8 | $128 |
| Lundbeck LLC | 6 | $101 |
| Amarin Pharma, Inc. | 5 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Shield Therapeutics Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 4 | $37 |
| Eisai Inc. | 2 | $36 |
| Sanofi | 1 | $28 |
| Endogastric Solutions, Inc | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,176 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 206 | $289,133 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 219 | $228,696 |
| EliquisApixaban | 258 | $228,093 |
| OzempicSemaglutide | 155 | $214,353 |
| FarxigaDapagliflozin Propanediol | 182 | $158,290 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 143 | $129,863 |
| JanuviaSitagliptin Phosphate | 142 | $109,262 |
| XareltoRivaroxaban | 98 | $95,257 |
| JardianceEmpagliflozin | 63 | $67,322 |
| RybelsusSemaglutide | 34 | $64,830 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $60,051 |
| TrulicityDulaglutide | 26 | $46,697 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $42,407 |
| MyrbetriqMirabegron | 40 | $39,420 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $32,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $332 | $335,830232 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $796 | $321,631361 claims |
| Novo NordiskOzempic, Rybelsus | $770 | $279,183189 claims |
| MerckJanumet Xr, Januvia, Janumet | $139 | $246,290296 claims |
| PfizerEliquis | $1,666 | $228,093258 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $825 | $176,625229 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $128 | $102,50299 claims |
| Johnson & JohnsonXarelto | $280 | $95,25798 claims |
| Astellas Pharma US IncMyrbetriq | $751 | $39,42040 claims |
| AbbVieLinzess | $319 | $12,63711 claims |
| NovartisEntresto | $200 | $8,18211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Cullman
- Randall QuinnCullman$5.4M
- Ben BostickCullman$1.5M
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.